Blog

ALLG, in 2024, continues its five decades of impact – Australasian Leukaemia and Lymphoma Group

Photo from Australasian Leukaemia and Lymphoma Group/LinkedIn

Jan 16, 2024, 16:56

ALLG, in 2024, continues its five decades of impact – Australasian Leukaemia and Lymphoma Group

Australasian Leukaemia & Lymphoma Group shared a post on LinkedIn.

“ALLG, in 2024, continues its five decades of impact.
With 6 new blood cancer trials opening in NZ and Australia, we can pursue further research for patients requiring better treatments, better lives.

Working collaboratively with our valued partners both locally and globally, our ultimate aim is to find a cure for this devastating disease.

Our collaborations with European colleagues like Prof Uwe Platzbecker (pictured with Delaine Smith and Prof Judith Trotman) enable us to bring important research to Australia and New Zealand. Visit us to find out more.”

Source: Australasian Leukaemia and Lymphoma Group/LinkedIn

Australasian Leukaemia & Lymphoma Group Australia blood cancer trials cancer Delaine Smith Judith Trotman New Zealand OncoDaily Oncology Uwe Platzbecker

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage